IGF 1 Interactions: Alcohol, Caffeine, Food & Other Compounds

"Interaction" is used loosely in general discussion, but in the published literature it usually means one of three distinct things: a study that deliberately co-administered two agents and measured an outcome, an observational analysis of an exposure (such as alcohol intake or diet) alongside markers of the growth hormone/IGF-1 axis, or a mechanistic argument about shared signalling pathways with no combination experiment behind it. This page keeps those categories separate. Where a combination has been studied, the finding is described with its citation. Where it has not, that absence is stated plainly and the pathway-level reasoning researchers apply is labelled as reasoning.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision. Nothing here describes protocols, timing or combinations for personal use.

What the Literature Actually Contains: An Overview

Alcohol and the IGF-1 Axis: What Studies Report

The most direct alcohol-related finding in this citation set comes from a 2025 report in which researchers examined chronic alcohol drinking and found impaired recognition memory alongside altered expression of insulin-associated genes in the medial prefrontal cortex (PMID 41400881). That study addressed the insulin/IGF family of signalling genes within brain tissue rather than administering IGF-1 as a treatment, so it describes how an alcohol exposure tracked with signalling-gene changes, not how alcohol modifies the effect of an administered peptide.

A point of frequent confusion deserves a note. A 2025 paper examined a Setaria viridis ethanol extract and reported attenuated muscle loss and reduced body fat in sarcopenic obesity through AMPK regulation in high-fat-diet-induced obese mice (PMID 40688596). The word "ethanol" there describes the solvent used to prepare a botanical extract; the study did not test alcohol consumption, and it should not be read as alcohol-interaction evidence.

What the verified literature does not contain is a controlled trial in which alcohol and IGF-1 were co-administered and a pharmacokinetic or pharmacodynamic interaction was quantified. Researchers who discuss the pairing generally reason from the observation that alcohol exposure has been linked to disturbances in insulin-associated signalling in brain tissue (PMID 41400881). That is mechanistic reasoning about overlapping pathways, and it is not the same as measured interaction data.

Caffeine: No Direct Co-Exposure Study Identified

Among the verified papers, none administered caffeine alongside IGF-1, and none measured caffeine's effect on circulating IGF-1 or on IGF-1 receptor signalling. This is a genuine evidence gap rather than a negative finding: absence of a study is not evidence of absence of an effect, and it is equally not evidence that no effect occurs.

The reasoning researchers typically apply — and it should be read as reasoning, not as a result — starts from energy-sensing pathways. Cellular energy status is coordinated in part through AMPK, the kinase that a 2025 mouse study identified as the pathway through which a botanical extract attenuated muscle loss and body fat reduction in sarcopenic obesity (PMID 40688596). Because AMPK signalling and anabolic growth-factor signalling both respond to nutrient and energy availability, commentators sometimes hypothesise that stimulants influencing energy metabolism could intersect with IGF-1 signalling. No study in this set tested that hypothesis.

Caffeine also appears in clinical environments where growth and lung development are studied; a 2024 review set out current prevention and treatment strategies in bronchopulmonary dysplasia (PMID 39053447), which illustrates how neonatal research tends to occur in multi-agent settings where isolating a single pairwise interaction is difficult. That review characterises a clinical field, not an IGF-1-plus-caffeine experiment.

Food, Fasting and Nutrient Signalling

Feeding state is the most heavily theorised influence on the IGF-1 axis, because insulin/IGF-like signalling evolved as a nutrient-sensing system. A WormBook chapter on intermediary metabolism described how insulin/IGF-like signalling in Caenorhabditis elegans coordinates nutrient storage and utilisation (PMID 19248207), and researchers frequently use that invertebrate framework when reasoning about why feeding and fasting states might shift growth-factor signalling. Extrapolating an invertebrate metabolic model to human physiology is an inference, and the chapter itself does not make clinical claims.

Glucose Handling

A 2021 review examined IGF-1 signalling in glucose metabolism in the specific context of colorectal cancer (PMID 34208601), describing how growth-factor signalling and glucose handling are interlinked at the cellular level. That review is disease-context-specific; it did not evaluate meals, macronutrient timing or fasting regimens in healthy subjects, and it was not designed to answer whether food alters the behaviour of administered IGF-1.

Gut Microbiota as a Dietary Intermediary

A 2018 review considered relationships between gut microbiota and IGF-1 (PMID 29362822), a line of work that matters to the food question because diet shapes microbial communities. Researchers reviewing this area proposed the microbiota as a possible intermediary between diet and circulating IGF-1 rather than as a demonstrated interaction mechanism in humans.

Dietary Composition in Animal Models

Diet-based models remain the workhorse of this area. In the 2025 mouse experiment already described, researchers reported that a botanical extract attenuated muscle loss and reduced body fat in high-fat-diet-induced obese mice through AMPK regulation (PMID 40688596). Such designs show that background diet can alter body-composition outcomes in animals, but they do not quantify a food–IGF-1 interaction.

Dietary IGF-1 and Food-Safety Literature

Questions about IGF-1 content in foods usually route into food-safety rather than endocrine literature. A 2009 review addressed health risks of genetically modified foods (PMID 18989835), covering how food-risk questions are evaluated; it is a food-safety assessment review and not a study of dietary IGF-1 absorption or of IGF-1 co-administration.

Other Compounds Studied Alongside IGF-1

Doxycycline

The clearest deliberate combination in this set is a 2026 study in which doxycycline and IGF-1 were investigated as a synergistic combination therapy for osteoarthritis disease modification (PMID 41401641). The study framed the pairing as complementary within a joint-disease model; it is preclinical combination research, and it does not establish outcomes outside that model.

Glucocorticoids and Chemotherapy Agents

Muscle-wasting models provide indirect context. A 2019 study reported that dexamethasone exacerbated cisplatin-induced muscle atrophy (PMID 30137654), an example of two agents producing a worse outcome together than either implied alone. Researchers cite such work when explaining that catabolic and anabolic signals converge on skeletal muscle, though that study examined dexamethasone and cisplatin, not IGF-1 administration.

Receptor-Level Antagonism

Interaction can also occur at the receptor. A 2025 report described viral insulin/IGF-like peptides that inhibited IGF-1 receptor signalling and thereby enhanced viral replication (PMID 40829596). The study is a useful demonstration that molecules structurally resembling IGF-1 can compete at the same receptor and produce inhibitory rather than stimulatory effects.

Exercise

Exercise is often discussed as a modifier of anabolic signalling. A 2020 review set out physical activity and exercise strategies to manage frailty (PMID 32234291), summarising how activity interventions are studied in ageing populations. That review addressed exercise programming and frailty outcomes; it was not a trial of exercise combined with administered IGF-1.

Interaction-Related Adverse Events: What Studies Report

Few of the verified papers were designed as safety studies, and none reported adverse events arising specifically from combining IGF-1 with alcohol, caffeine or food. The adjacent signals researchers point to are: worsened muscle atrophy when dexamethasone was added to cisplatin exposure in a rodent model (PMID 30137654); impaired recognition memory with altered insulin-associated genes following chronic alcohol drinking (PMID 41400881); and enhanced viral replication when IGF-1 receptor signalling was inhibited by viral insulin/IGF-like peptides (PMID 40829596). On the excess side of the axis, a review of extra-hepatic acromegaly described disease arising from sources of growth hormone/IGF-1 excess outside the usual pituitary–hepatic route (PMID 30349613), which is the clinical literature most often cited when discussing consequences of sustained IGF-1 elevation.

How to Read This Evidence Base

• Model species matter. Nutrient-sensing conclusions drawn in C. elegans (PMID 19248207) and body-composition findings in high-fat-diet mice (PMID 40688596) are not human interaction data.
• Reviews are syntheses, not experiments. The microbiota review (PMID 29362822) and the glucose-metabolism review (PMID 34208601) summarise fields rather than measuring a pairing.
• Combination therapy is context-bound. The doxycycline-plus-IGF-1 work was framed around osteoarthritis disease modification (PMID 41401641) and describes that setting only.
• Silence is silence. No caffeine co-exposure result is reported here because no such study appears in this verified set.

Readers interested in the wider background of this signalling axis can continue with the overview at /learn/igf-1/.

References

• Chronic Alcohol Drinking Impairs Recognition Memory And Insulin-Associated Genes In The Medial Prefrontal Cortex (Molecular Neurobiology, 2025)
• Setaria viridis Ethanol Extract Attenuates Muscle Loss and Body Fat Reduction in Sarcopenic Obesity by Regulating AMPK in High-Fat Diet-Induced Obese Mice (Food Science & Nutrition, 2025)
• Intermediary metabolism (WormBook, 2009)
• Gut Microbiota and IGF-1 (Calcified Tissue International, 2018)
• Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer (International Journal of Molecular Sciences, 2021)
• Doxycycline and IGF-1 as a synergistic combination therapy for OA disease modification (Biomedicine & Pharmacotherapy, 2026)
• Dexamethasone exacerbates cisplatin-induced muscle atrophy (Clinical and Experimental Pharmacology & Physiology, 2019)
• Viral insulin/IGF-like peptides inhibit IGF-1 receptor signaling to enhance viral replication (Cell Reports, 2025)
• Physical activity and exercise: Strategies to manage frailty (Redox Biology, 2020)
• Extra-hepatic Acromegaly (European Endocrinology, 2013)
• BPD: Latest Strategies of Prevention and Treatment (Neonatology, 2024)
• Health risks of genetically modified foods (Critical Reviews in Food Science and Nutrition, 2009)